International Journal of Molecular Sciences · 2018 · 30 citations · 47 references
Life SciencesOncologyPharmacologyApoptosisCell SignalingSignal TransductionApoptosis In CancerCancer Cell SignalingCell Cycle SignalingCyclin-dependent KinasesOncogenic Signaling PathwaysSignal Transduction In CancerCancer Cell Proliferation InhibitionCancer Signaling PathwaysDual-specificity PhosphatasesExtracellular Signal-regulated Kinase PathwayMek InhibitorsMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase InactivationMitogen-activated Protein Kinase Pathways
NSC 95397, a quinone-based small molecule compound, has been identified as an inhibitor for dual-specificity phosphatases, including mitogen-activated protein kinase phosphatase-1 (MKP-1). MKP-1 is known to inactivate mitogen-activated protein kinases by dephosphorylating both of their threonine and tyrosine residues. Moreover, owing to their participation in tumorigenesis and drug resistance in colon cancer cells, MKP-1 is an attractive therapeutic target for colon cancer treatment. We therefore investigated the inhibitory activity of NSC 95397 against three colon cancer cell lines including SW480, SW620, and DLD-1, and their underlying mechanisms. The results demonstrated that NSC 95397 reduced cell viability and anchorage-independent growth of all the three colon cancer cell lines through inhibited proliferation and induced apoptosis via regulating cell-cycle-related proteins, including p21, cyclin-dependent kinases, and caspases. Besides, by using mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126, we provided mechanistic evidence that the antineoplastic effects of NSC 95397 were achieved via inhibiting MKP-1 activity followed by ERK1/2 phosphorylation. Conclusively, our results indicated that NSC 95397 might serve as an effective therapeutic intervention for colon cancer through regulating MKP-1 and ERK1/2 pathway.
47
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Mutations in the p53 gene occur in diverse human tumour types
Janice Nigro, Suzanne J. Baker, Antonette C. Preisinger et al. · Nature · 1989 · 2.8K citations · Full text
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Pumin Zhang, J. Wade Harper, Stephen J. Elledge et al. · Cell · 1995 · 2.1K citations · Full text
p53 mutations in colorectal cancer.
Nanda R. Rodrigues, Andrew Rowan, Mark E. Smith et al. · Proceedings of the National Academy of Sciences · 1990 · 1K citations